261 related articles for article (PubMed ID: 34347201)
1. Safety of apixaban for venous thromboembolic primary prophylaxis in patients with newly diagnosed malignant glioma.
Thomas AA; Wright H; Chan K; Ross H; Prasad P; Goodwin A; Holmes CE
J Thromb Thrombolysis; 2022 Feb; 53(2):479-484. PubMed ID: 34347201
[TBL] [Abstract][Full Text] [Related]
2. [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
Gómez Arrayas I; Suárez Fernández C; Gómez Cerezo JF; Betegón Nicolás L; de Salas-Cansado M; Rubio-Terrés C
Rev Esp Salud Publica; 2012 Dec; 86(6):601-12. PubMed ID: 23325135
[TBL] [Abstract][Full Text] [Related]
3. Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-up.
Larsen TL; Garresori H; Brekke J; Enden T; Frøen H; Jacobsen EM; Quist-Paulsen P; Porojnicu AC; Ree AH; Torfoss D; Osvik Velle E; Skuterud Wik H; Ghanima W; Sandset PM; Dahm AEA
J Thromb Haemost; 2022 May; 20(5):1166-1181. PubMed ID: 35114046
[TBL] [Abstract][Full Text] [Related]
4. Is Apixaban Safe and Effective for Venous Thromboembolism Prophylaxis After Primary Total Hip and Total Knee Arthroplasties?
Rooney T; Barrack RL; Clohisy JC; Nunley RM; Lawrie CM
J Arthroplasty; 2021 Jul; 36(7S):S328-S331. PubMed ID: 33888386
[TBL] [Abstract][Full Text] [Related]
5. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
McBane Ii R; Loprinzi CL; Ashrani A; Perez-Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Le-Rademacher JG; Wysokinski WE
Thromb Haemost; 2017 Oct; 117(10):1952-1961. PubMed ID: 28837207
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of apixaban for primary prevention of thromboembolism in patients with cancer and a central venous catheter: A subgroup analysis of the AVERT Trial.
Brandt W; Brown C; Wang TF; Tagalakis V; Shivakumar S; Ciuffini LA; Mallick R; Wells PS; Carrier M
Thromb Res; 2022 Aug; 216():8-10. PubMed ID: 35660801
[TBL] [Abstract][Full Text] [Related]
7. Extending venous thromboembolism secondary prevention with apixaban in cancer patients: The EVE trial.
McBane RD; Loprinzi CL; Ashrani A; Lenz CJ; Houghton D; Zemla T; Le-Rademacher JG; Wysokinski WE
Eur J Haematol; 2020 Feb; 104(2):88-96. PubMed ID: 31606897
[TBL] [Abstract][Full Text] [Related]
8. Safety and Effectiveness of Apixaban in Japanese Patients With Venous Thromboembolism in Clinical Practice - A Post-Marketing Surveillance.
Yamada N; Mo M; Ohsawa A; Sato M; Umeyama M; Shima D; Nakamura M
Circ J; 2021 Nov; 85(12):2201-2207. PubMed ID: 33994408
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery.
Imberti D; Gallerani M; Manfredini R
J Thromb Thrombolysis; 2012 Aug; 34(2):208-13. PubMed ID: 22466929
[TBL] [Abstract][Full Text] [Related]
10. Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study.
Mahé I; Agnelli G; Ay C; Bamias A; Becattini C; Carrier M; Chapelle C; Cohen AT; Girard P; Huisman MV; Klok FA; López-Núñez JJ; Maraveyas A; Mayeur D; Mir O; Monreal M; Righini M; Samama CM; Syrigos K; Szmit S; Torbicki A; Verhamme P; Vicaut E; Wang TF; Meyer G; Laporte S
Thromb Haemost; 2022 Apr; 122(4):646-656. PubMed ID: 34535037
[TBL] [Abstract][Full Text] [Related]
11. Thromboprophylaxis for patients with newly diagnosed vs. recurrent cancers: a post-hoc analysis of the avert trial.
Zhang J; Atalla M; Mallick R; Wells PS; Carrier M
J Thromb Thrombolysis; 2021 Apr; 51(3):720-724. PubMed ID: 33079379
[TBL] [Abstract][Full Text] [Related]
12. Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
Cornell RF; Goldhaber SZ; Engelhardt BG; Moslehi J; Jagasia M; Harrell S; Rubinstein SM; Hall R; Wyatt H; Piazza G
Br J Haematol; 2020 Aug; 190(4):555-561. PubMed ID: 32314352
[TBL] [Abstract][Full Text] [Related]
13. A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.
Revankar N; Patterson J; Kadambi A; Raymond V; El-Hadi W
Postgrad Med; 2013 Jul; 125(4):141-53. PubMed ID: 23933902
[TBL] [Abstract][Full Text] [Related]
14. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
[TBL] [Abstract][Full Text] [Related]
15. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.
Goldhaber SZ; Leizorovicz A; Kakkar AK; Haas SK; Merli G; Knabb RM; Weitz JI;
N Engl J Med; 2011 Dec; 365(23):2167-77. PubMed ID: 22077144
[TBL] [Abstract][Full Text] [Related]
16. Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism.
Hannevik TL; Brekke J; Enden T; Frøen H; Garresori H; Jacobsen EM; Paulsen PQ; Porojnicu AC; Ree AH; Torfoss D; Velle EO; Wik HS; Ghanima W; Sandset PM; Dahm AEA
Thromb Res; 2020 Dec; 196():238-244. PubMed ID: 32919178
[TBL] [Abstract][Full Text] [Related]
17. Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada.
Quon P; Le HH; Raymond V; Mtibaa M; Moshyk A
J Med Econ; 2016 Jun; 19(6):557-67. PubMed ID: 26761644
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice.
Weycker D; Li X; Wygant GD; Lee T; Hamilton M; Luo X; Vo L; Mardekian J; Pan X; Burns L; Atwood M; Hanau A; Cohen AT
Thromb Haemost; 2018 Nov; 118(11):1951-1961. PubMed ID: 30357780
[TBL] [Abstract][Full Text] [Related]
19. Apixaban: An Optimal Agent for the Treatment of Cancer-Associated Venous Thromboembolism?
Grilusová K; Bolek T; Škorňová I; Stančiaková L; Mikušová V; Kubisz P; Galajda P; Staško J; Samoš M; Mokáň M
Am J Ther; 2021 Sep; 29(2):e212-e218. PubMed ID: 35389573
[TBL] [Abstract][Full Text] [Related]
20. Long-term benefits of preventing venous thromboembolic events.
Cohen AT
Curr Med Res Opin; 2012 Jun; 28(6):877-89. PubMed ID: 22533680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
